Gossamer Bio, Inc. Stock: price and insider trades · United States

Gossamer Bio, Inc. (NASDAQ: GOSS) is a United States-based, clinical-stage biopharmaceutical company headquartered in San Diego, California. The company was founded in 2015, originally as FSG Bio, Inc., and was later launched publicly in 2018 by former Receptos executives. From the outset, Gossamer Bio built its strategy around a combination of in-licensing, clinical development, and targeted therapeutic innovation for areas of high unmet medical need. Today, the company is far more focused than in its early years: its core story is centered on seralutinib, an investigational drug candidate aimed primarily at pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

From a business-model perspective, Gossamer Bio remains a classic development-stage biotech rather than a diversified commercial pharmaceutical company. Its value proposition depends heavily on the clinical, regulatory, and eventual commercial progress of seralutinib. That concentration creates meaningful upside if the asset succeeds, but it also leaves the equity highly exposed to binary clinical outcomes and regulatory decisions. The company emphasizes its scientific foundation in immunology, translational research, and rare-disease development, supported by a management team with deep biotech and pharma experience.